Even though we could only measure a limited impact of LAG-3/PD-L1 blockade on the immune response, the treatment significantly diminishes blood parasitemia (~30% from day ~12 and on), which may be essential in limiting the excessive inflammation associated with severe malaria. The gene discussed is CD274; the disease is malaria.